NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.
Reference is made to the stock exchange announcement from Navamedic ASA (the
"Company") published on 27 May 2020 regarding the commencement of a subsequent
offering of up to 526,000 new shares in the Company (the "Offer Shares") at a
subscription price of NOK 19.00 per share (the "Subsequent Offering").
The subscription period in the Subsequent Offering expired today on 11 June 2020
at 16:30 hours (CET).
Preliminary counting indicates that the Company has received subscriptions for
approximately 446,478 Offer Shares in the Subsequent Offering. The preliminary
counting indicates no over-subscriptions have been made.
The final allocation of the Offer Shares in the Subsequent Offering is expected
to take place tomorrow on 12 June 2020 in accordance with the allocation
criteria set out in the prospectus dated 27 May 2020, comprising a registration
document, a securities note and a summary (jointly the "Prospectus"). The final
result of the Subsequent Offering will be published shortly thereafter, and
letters regarding allocation of Offer Shares and the corresponding subscription
amount to be paid by each subscriber, are expected to be distributed on or about
the same day.
The due date for payment of the Offer Shares is expected to be on or about 16
SpareBank 1 Markets AS is acting as manager in the Subsequent Offering.
Advokatfirmaet Thommessen AS is acting as legal advisor to the Company in
connection with the Subsequent Offering.
For further information about the Company, please contact:
Kathrine G. Andreassen, CEO, Navamedic,
Mobile: +47 951 78 680
Lars Hjarrand, CFO, Navamedic,
Mobile: +47 917 62 842
For information about the Subsequent Offering please contact the manager:
SpareBank 1 Market AS, tel +47 24 14 74 70
Navamedic ASA is a preferred, full-service provider of high-quality healthcare
products to hospitals and pharmacies. Navamedic meets the specific medical needs
of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please visit
These materials do not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the "U.S.
Securities Act"). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to "qualified
institutional buyers" as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.
In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State. The expression "Prospectus
Regulation" means Regulation (EU) 2017/1129 (together with any applicable
implementing measures in any Member State).
In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as "Relevant Persons"). These materials are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.
Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as "anticipate", "believe",
"continue", "estimate", "expect", "intends", "may", "should", "will" and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.
This announcement is made by and, and is the responsibility of, the Company. The
Manager is acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.
Neither the Manager nor any of its respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.
This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the Manager
nor any of its respective affiliates accepts any liability arising from the use
of this announcement.
The offering of the securities referred to in this announcement is made by means
of the Prospectus. This announcement is an advertisement and is not a prospectus
for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of
the Council of 14 June 2017 on prospectuses to be published when securities are
offered to the public or admitted to trading on a regulated market, and
repealing Directive 2003/71/EC (as amended) as implemented in any Member State.
Investors should not subscribe for any securities referred to in this
announcement except on the basis of information contained in the Prospectus.
Copies of the Prospectus are available from the Company's registered office and,
subject to certain exceptions, on the website of SpareBank 1 Markets
Each of the Company, the Manager and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.
The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.
This information is subject of the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.